Earnings Feed
Start Free
ACADIA PHARMACEUTICALS INC·4

Jun 1, 6:00 PM ET

Ndu Adora 4

Research Summary

AI-generated summary

Updated

ACADIA (ACAD) Director Ndu Adora Exercises Options, Receives RSUs

What Happened

  • Ndu Adora, a director of ACADIA Pharmaceuticals (ACAD), reported derivative activity on May 29, 2026. The filing shows an exercise/conversion of 8,107 derivative shares and a matching disposition of 8,107 shares at $0.00, plus grants/awards of 16,004 and 9,311 restricted stock units (RSUs) — a total of 25,315 RSUs acquired/awarded. Prices shown are $0.00 or N/A; no cash value is reported in the filing.

Key Details

  • Transaction date: May 29, 2026; Form 4 filed June 1, 2026. The filing does not indicate a late filing.
  • Reported transactions:
    • 8,107 shares: exercise/conversion of derivative (code M), acquired (N/A) and concurrently disposed at $0.00 (derivative).
    • 16,004 RSUs: grant/award (code A), acquired at $0.00 (derivative).
    • 9,311 RSUs: grant/award (code A), acquired at $0.00 (derivative).
  • Shares owned after transaction: not specified in the provided summary of the filing.
  • Footnotes of note:
    • F1: Each RSU represents a contingent right to one share of common stock.
    • F2: The RSUs vested in full on May 29, 2026 (the date of the annual meeting).
    • F3: Option tranches (where applicable) vest quarterly over one year after grant, with final tranche earlier of one year or next annual meeting.
    • F4: The RSUs will vest in full on the earlier of one year following grant or the next annual meeting.
  • The disposal at $0.00 is shown as a derivative disposition; such zero-dollar filings commonly reflect net settlement or shares withheld for taxes, but the filing itself does not state the reason.

Context

  • These transactions are primarily awards/vesting and a derivative conversion — acquisitions rather than an open-market purchase or sale. Awards and vested RSUs signal issuance/compensation events rather than an obvious market-confidence purchase by the insider.
  • For retail investors: awards/vesting increase insider-held equity but do not necessarily indicate the director is buying additional stock with personal funds. The filing provides share counts but no dollar values for these entries.